Hims & Hers Health (HIMS) Net Equity Issued and Repurchased (2020)
Hims & Hers Health (HIMS) reported Net Equity Issued and Repurchased of -$27000.0 for Q4 2020, down 100.19% sequentially from $14.4 million in Q3 2020.
Hims & Hers Health (HIMS) Net Equity Issued and Repurchased (2020) Analysis & Trends
Hims & Hers Health (HIMS) has 1 years of Net Equity Issued and Repurchased data on file, last reported at -$27000.0 in Q4 2020.
- For the quarter ending Q4 2020, Net Equity Issued and Repurchased changed N/A year-over-year to -$27000.0; the trailing twelve-month figure through Sep 2021 stood at -$27000.0 (changed N/A YoY), and the FY2020 full-year result was $51.9 million, down 49.4% from the prior year.
- Net Equity Issued and Repurchased eased to -$27000.0 in Q4 2020, from $14.4 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $31.6 million in Q1 2020 to a low of -$27000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 500,000.00 |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 23.60 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -27,000.00 |
| Dec 31, 2020 | -27,000.00 |
| Sep 30, 2020 | 14.38 Mn |
| Sep 30, 2020 | 14.38 Mn |
| Jun 30, 2020 | 5.95 Mn |
| Jun 30, 2020 | 5.95 Mn |
| Mar 31, 2020 | 31.60 Mn |
| Mar 31, 2020 | 31.60 Mn |